Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.

A. De Luca, D., Dunn,, Maurizio Zazzi, R, Camacho , Carlo Torti, I., Fanti,, A Sonnerborg, F.M., Codoñer,, K Van Laethem, Anne-mieke Vandamme, L., Bansi,, V., Ghisetti, , D.A.M.C., Van De Vijver, , D., Asboe,, M.C.F., Prosperi,, S., Di Giambenedetto,

Research output: Contribution to journalArticle

46 Citations (Scopus)


HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.
Original languageUnknown
Pages (from-to)1216-20
JournalThe Journal of infectious diseases
Issue number8
Publication statusPublished - 1 Jan 2013

Cite this